Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Top Cited Papers
- 30 January 2009
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 373 (9660), 309-317
- https://doi.org/10.1016/s0140-6736(08)61845-0
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance DoseCirculation, 2008
- Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary SyndromeThe American Journal of Cardiology, 2008
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJournal of Thrombosis and Haemostasis, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2007
- Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young ageBMC Medical Genetics, 2007
- Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary StentingJournal of the American College of Cardiology, 2006
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- Clopidogrel for Coronary StentingCirculation, 2003
- P2Y12, a New Platelet ADP Receptor, Target of ClopidogrelBiochemical and Biophysical Research Communications, 2001
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionThe New England Journal of Medicine, 1985